Takeda and TiGenix in licensing deal ex-USA for Crohn's disease drug Cx601

5 July 2016
2019_biotech_test_vial_discovery_big

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) and Belgian biopharma firm TiGenix (Euronext Brussels: TIG) have entered into a licensing, development and commercialization agreement for Crohn’s disease treatment Cx601 outside the USA.

TiGenix will receive an upfront cash payment of 25 million euros ($27.86 million) and will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of 355 million euros and double-digit royalties on net sales by Takeda.

The first anticipated milestone payment is 15 million euros upon obtaining the Marketing Authorization of Cx601 in Europe. Takeda will also make an equity investment of €10 million in the share capital of TiGenix within the next 12 months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology